Merita Kucuku*

Freelance Consultant, Presentation in the Meeting Global Conference on Vaccines Research and Development and Global Conference on Nursing and Health Care (Second Part), Dec. 05- 06 2022, Seville- Spain

*Corresponding Author: Merita Kucuku, Presentation in the Meeting Global Conference on Vaccines Research and Development and Global Conference on Nursing and Health Care (Second Part), Dec. 05- 06 2022, Seville- Spain.

Received: November 04, 2025; Published: November 27, 2025

Abstract

The adjuvants used for many years for increasing the immune response have been aluminum salt. This adjuvants fill out the conditions for safety and efficacy for increasing the immune response [1-4]. Adjuvants are characterized by several parameters that must be taken into consideration for the safety and efficacy of human vaccines. Some of the parameters that characterize adjuvants are critical and their identification is of particular importance. The identification of these parameters is done during the assessment of the quality of vaccines/adjuvants. During the assessment of the quality of vaccines, other parameters should also be included, which should be routine analyses. This assessment is very important because the quality, safety and efficacy of vaccines are related to the life and prevention of various infections of the population. The characteristic parameters of adjuvants depend on the nature of the adjuvants, which can be of chemical or biochemical composition [5].

Keywords: Adjuvant; Analysis; Toxicity; Safety; Benefit; Risk

References

1. Estephan L., et al. “A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Medigen COVID-19 protein vaccine”. Vaccine15 (2023): 2615-2629.
2. Alessio Facciolà., et al. “An Overview of Vaccine Adjuvants: Current Evidence and Future Perspectives”. Vaccines (Basel)5 (2022): 819.
3. He P., et al. “Advances in Aluminium hydroxide- based adjuvant research and its mechanism”. Human Vaccines and Immunotherapeutics2 (2015): 477-488.
4. “Center For Disease Control and Prevention, Adjuvants and vaccines”.
5. Petrovsky N. “Comparative Safety of Vaccine Adjuvants: A summary of Current Evidence and Future Needs”. Drug Safety11 (2015): 1059-1074.
6. Kucuku M. “Adjuvants, their role and safety profile in vaccines”. EC Clinical and Medical Case Reports5 (2023).
7. Hervé C., et al. “The how’s and what`s of vaccine reactogenicity”. npj Vaccines 4 (2019): 39.
8. Da Silva F T., et al. “Safety assessment of adjuvanted vaccines: Methodological considerations”. Human Vaccine Immunotherapy7 (2015): 1814-1824.
9. The European Agency for the Evaluation on Medicinal Products Evaluation of Medicines for Human Use, Guidelines on adjuvants in vaccines, London 25 March (2004).

Citation

Citation: Merita Kucuku. “Parameters of Adjuvant in the Safety Profile of Human Vaccines in Relation to Toxicity".Acta Scientific Microbiology 8.12 (2025): 48-51.

Copyright

Copyright: © 2025 Merita Kucuku. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.